CN102495215B - Kit for quantitatively detecting tumor necrosis factor alpha - Google Patents
Kit for quantitatively detecting tumor necrosis factor alpha Download PDFInfo
- Publication number
- CN102495215B CN102495215B CN201110399728.2A CN201110399728A CN102495215B CN 102495215 B CN102495215 B CN 102495215B CN 201110399728 A CN201110399728 A CN 201110399728A CN 102495215 B CN102495215 B CN 102495215B
- Authority
- CN
- China
- Prior art keywords
- tnf
- container
- kit
- add
- magnetic bead
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 40
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title claims abstract description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 30
- 102000004190 Enzymes Human genes 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- 238000007885 magnetic separation Methods 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 239000011324 bead Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000008213 purified water Substances 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 238000013016 damping Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012744 reinforcing agent Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 150000001718 carbodiimides Chemical class 0.000 claims description 6
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- -1 TNF-α compound Chemical class 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 9
- 239000006249 magnetic particle Substances 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000002860 competitive effect Effects 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 9
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a diagnosis kit for quantitatively detecting a tumor necrosis factor (TNF) alpha, and a detection method thereof. The kit comprises a TNF-alpha magnetic separation reagent, an enzyme-labeled antibody, a reinforcer, a calibration substance, a control substance, a concentrated solution and a substrate. The kit combined with an immune magnetic particle separation technology and a competitive enzyme-linked immune technology has high detection sensitivity and specificity; furthermore, the detection time is shortened greatly; a plurality of biologic samples can be detected within 10 minutes; and samples, such as urine, serum and the like, can be directly detected without being pretreated.
Description
Technical field
The present invention relates to measure a kind of diagnostic kit and detection method thereof of quantitative detection tumor necrosis factor α.
Background technology
TNF, is called for short TNF, is a kind of small molecular protein of being secreted by macrophage.Tumor necrosis factor α (TNF-α) is mainly secreted by monokaryon one macrophage; TNF-β is mainly by the T lymphocytic emiocytosis activating, and both have similar pyrogenicity.Low dose is unimodal heat, and heavy dose is double quotidian fever; TNF all can stimulate the generation of IL-1 in vivo and in vitro.
The mankind's TNF-α gene is about 2.76kb, and mouse is 2.78kb, and structure is closely similar, by 4 extrons and 3 intrones, forms, closely chain with mhc gene group, is positioned respectively on the 6th pair and the 17th pair of chromosome.Within 1984, from the cells such as HL-60, U937, clone successful rHu TNF-α cDNA, and in Escherichia coli, obtain high expressed.HumanTNF-α's precursor is comprised of 233 amino acid residues, and containing the signal peptide of 76 amino acid residues, excision signal peptide after ripening type TNF-α is 157 amino acid residues, non-glycosylated, the 69th and 101 two halfcystines formation intramolecular disulfide bonds.RHu TNF-alpha molecule amount is 17kDa.Ripe mouse TNF-α and rMu TNF-α form homology by 79% amino acid, and the biological action of TNF-α is like the obvious species specificity of nothing.
TNF-α has participated in the biological process in multiple body, can kill and wound or inhibition tumor cell, improves the phagocytic activity of neutrophil leucocyte, and antiviral bacterium infects, and promotes myeloid leukemia cell to macrophage differentiation etc.Application TNF-α starts the clinical II phase to be tested at aspects such as treatment tumours, also can with IL-2 therapeutic alliance tumour, think that at present the curative effect of systemic administration is not as good as local application, the latter is as intralesional injection, local concentration is high and spinoff is also lighter.Adopted in recent years tnf gene treatment to start the tumours such as melanoma to carry out clinical verification.TNF is also relevant with the lesion degree of some clinical some diseases, and for example Kaschin-Beck disease, colitis, meningitis and asthma etc., can carry out by detecting the biochemical indicators such as TNF-α the occurrence degree of analysis of disease clinically.
Past take and puts the detection kit of exempting from as the detection TNF of representative and be subject to methodological restriction, its sensitivity and antijamming capability wretched insufficiency, have very large drawback, substantially withdraw from the market, applying at present more is enzyme linked immunosorbent detection technology and chemiluminescence.It is continue Enzyme-multiplied immune technique and the emerging technology growing up after putting immune technology the eighties that chemiluminescence rises in eighties of last century, due to its high sensitivity, high specific, while method is easy, quick, mark bond is stable, the features such as "dead" isotope damage and pollution, have obtained develop rapidly in recent years.
Magnetic particle separation enzyme-linked immunoassay technology is a kind ofly to take magnetic particle as solid phase carrier of separating, immune magnetic particle isolation technics is combined with enzyme linked immunosorbent detection technology and a kind of Novel immune detection method of setting up.Traditional E LISA method, the association reaction of antigen, antibody carries out on solid phase (elisa plate reacting hole) surface, and magnetic particle separation enzyme-linked immunoassay, the association reaction of antigen, antibody also carries out under the condition of approximate liquid phase, thereby reaction is fast, thoroughly.Compare with traditional E LISA and have highly sensitively, detect few advantage of used time.
Summary of the invention
The technical issues that need to address of the present invention are to provide diagnostic kit and the detection method thereof of a kind of quantitative detection TNF-α, adopt this kit to carry out TNF-α detection and there is higher sensitivity and specificity, and the time of shorter acquisition testing result and easier mode of operation.
Kit provided by the invention, its reagent comprising has TNF-α magnetic separation agent, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate.
Described magnetic separation agent contains the magnetic microsphere that is marked with TNF-alpha monoclonal antibodies.
Described enzyme labelled antibody is the TNF-alpha monoclonal antibodies that contains horseradish peroxidase-labeled.
Described reinforcing agent is the damping fluid that contains Tris.
Described calibration object and control product are the solution that contains a certain amount of TNF-α antigen.
Described concentrate is the damping fluid that contains TWEEN-20 and Proclin-300.
Described substrate is enzyme-catalyzed chemical luminescence substrate.
The immue quantitative detection reagent box of TNF-α of the present invention, is preferably prepared from as follows:
The first step: the preparation process of magnetic separation agent:
1,1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mgTNF-alpha monoclonal antibodies is dissolved in PH 9.5 to cumulative volume be 1ml;
2, with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, join in the antibody-solutions of step 1, put room temperature 90min;
3, step 2 antibody-solutions is joined in concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4, get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack special, through magnet adsorption, after 2 minutes, draw supernatant;
5, add 1.5ml PH9.50.1mol/L PB at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times; The antibody-solutions that step 3 is obtained joins in above-mentioned magnetic bead, mixes rear room temperature reaction 4 hours;
6,37 ℃ of the TRIS solution 15 minutes that add 0.3ml 1mol/L;
7, add 1.5ml PH 7.20.1mol/L PB to clean the magnetic bead of mark at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times;
8, with 100ml magnetic bead, preserve liquid magnetic bead is proceeded to 125ml vial; It is (being mass volume ratio) 0.1%BSA that magnetic bead is preserved formula of liquid, 0.05% Tween-20,0.02%NaN3,20% ethanol, 4 ℃ of preservations.
9, by magnetic bead buffer solution, the volume ratio according to 1: 1 mixes magnetic separation agent step 8 being obtained, and obtains magnetic separation agent in kit of the present invention; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Second step: enzyme labelled antibody preparation process:
1,2.5mgTNF-alpha monoclonal antibodies is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml 20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2, the solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally by the conjugate of the horseradish peroxidase of collecting and TNF-alpha monoclonal antibodies, with enzyme labelled antibody dilution, the volume ratio with 1: 1000 mixes, and obtains enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
The 3rd step: reinforcing agent preparation steps:
1, take TRIS1.56g and NaCl 4.23g in 1L container; With pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker of 10ml purified water, pour in above-mentioned 1L container;
2, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely, adjust PH, control PH between 7.35-7.45;
3, take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, filters with 0.2um filter.
The 4th step:
The preparation of calibration object and the product of control:
Calibration object concentration is respectively 0.10,0.20,0.40,0.80,1.60ng/ml; Control product concentration is respectively 0.20,0.80ng/ml.
The 5th step:
Concentrate preparation steps, preparation 1L:
1, take TRIS 12.54g and NaCl 325.6g in 1L container;
2, after taking 5g Tween-20 and adding 20ml water in 100ml container it is dissolved completely, pour in above-mentioned 1L container;
3, with pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker that fills 10ml purified water, pour in above-mentioned 1L container;
4, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely;
5, adjust PH, control its scope between 7.35-7.45;
6, last constant volume 1000ml, filters and get final product with 0.2um filter after dissolving completely.
The 6th step:
Substrate preparation steps, preparation 1L:
1, take TRIS 2.35g, NaCl 6.41g, Na
2sO
30.002g and Proclin-3000.2ml are in 1L beaker;
2, with graduated cylinder, measure 600ml purified water in 1L beaker, fully stir, until dissolve completely, adjust PH, control its scope between 7.95-8.05;
3, add after 250ml Lumi-Phos 530, with 0.2um filter, filter and collect filtrate, by purified water, be settled to 1000ml, after mixing and get final product.
Main innovation part of the present invention is:
1, kit of the present invention combines chemiluminescence with immune magnetic particle, and a kind of reaction system that approaches homogeneous phase is provided, and compared with prior art, kit of the present invention has higher detection sensitivity and specificity, and has reached preferably performance parameter.
2, the invention discloses a kind of new special-purpose reinforcing agent and concentrate, make course of reaction more reliable and more stable, experimental data is sensitive effectively can be accurate to 0.01ng, when enhancing product performance, and greatly reduces cost of products;
3, the TNF-α magnetic separation agent in this kit, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate are all the optimization formulas under this reaction system, giving the use effect phase of this kit and detecting performance provides powerful guarantee.
4, this kit adopts immune magnetic particle isolation technics to be combined with competitive enzyme-linked immune technology, compare with the kit of prior art, greatly shorten detection time, can in 10 minutes, detect several biological specimens, for urine, serum equal samples, can not need pre-treatment directly to detect.
Embodiment
Embodiment 1,
One, TNF-α magnetic separation agent preparation process:
1,1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mgTNF-alpha monoclonal antibodies (Santa Cruz company product) is dissolved in PH 9.5 to cumulative volume be 1ml;
2, with the disuccinimidyl suberate that liquid-transfering gun is drawn in step 1, join in the antibody-solutions of step 1, put room temperature 90min;
3, the solution of step 2 is joined in Centricon-10 concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4, get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack special, through magnet adsorption, after 2 minutes, draw supernatant; Magnetic bead is the conventional magnetic bead in this area, preferred concentration 25mg/mL, and diameter is 800nm.
5, add 1.5ml PH9.50.1mol/L PB at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times; The antibody-solutions that step 4 is obtained joins in above-mentioned magnetic bead, mixes rear room temperature reaction 4 hours;
6,37 ℃ of the TRIS solution 15 minutes that add 0.3ml 1mol/L;
7, add 1.5ml PH 7.20.1mol/L PB to clean the magnetic bead of mark at every turn, mix 30 seconds, added, remove supernatant, repetitive operation 3 times;
8, with 100ml magnetic bead, preserve liquid magnetic bead is proceeded to 125ml vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid, 0.05% Tween-20,0.02%NaN3,20% ethanol (being mass volume ratio), 4 ℃ of preservations.
9, by magnetic bead buffer solution, the volume ratio according to 1: 1 mixes magnetic separation agent step 8 being obtained, and obtains magnetic separation agent in kit of the present invention; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Embodiment 2
One, the preparation process of enzyme labelled antibody:
1,2.5mgTNF-alpha monoclonal antibodies is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml 20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2, the solution of step 1 is packed in bag filter, to the PH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally by the conjugate of the horseradish peroxidase of collecting and TNF-alpha monoclonal antibodies, with enzyme labelled antibody dilution, the volume ratio with 1: 1000 mixes, and obtains enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L.
Embodiment 3
Reinforcing agent preparation steps:
1, take TRIS1.56g and NaCl 4.23g in 1L container; With pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker of 10ml purified water, pour in above-mentioned 1L container;
2, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely, adjust PH, control PH between 7.35-7.45;
3, take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, filters with 0.2um filter.Mak33 is the commercial reagent of Roche Holding Ag.
Embodiment 4
The preparation steps of calibration object and the product of control:
1, peak: maximum concentration point is X, impact point concentration is A, B, C, D, E, F, while preparing the solution of V volume, need add the volume of raw material for being respectively: table 1
| Concentration | Add calibration object dilution volume | Add X volume |
| A | V-A*V/X | A*V/X |
| B | V-B*V/X | B*V/X |
| C | V-C*V/X | C*V/X |
| D | V-D*V/X | D*V/X |
| E | V-E*V/X | E*V/X |
| F | V-F*V/X | F*V/X |
2, TNF-α immue quantitative detection reagent box TNF-α calibration object raw material (being purchased from Santa Cruz company) is mixed with by purified water that concentration point is 0.10,0.20,0.40,0.80,1.60ng/ml; Control product with the concentration point of purified water preparation be 0.20,0.80ng/ml.
3, after dissolving completely, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months.
Embodiment 5:
Concentrate preparation steps:
1, take TRIS 12.54g and NaCl 325.6g in 1L container;
2, after taking 5g Tween-20 and adding suitable quantity of water in 100ml container it is dissolved completely, pour in said vesse;
3, with pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker that fills 10ml purified water, pour in above-mentioned 1L container;
4, with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely;
5, with HCL or NaOH, adjust PH, measure its scope between 7.35-7.45;
6, last constant volume 1000ml, surveys pH value, and scope meets the requirements between 7.35-7.45, after dissolving completely, with 0.2um filter, filters; After having filtered, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months;
Embodiment 6
Substrate formulation operations step:
1, take TRIS 2.35g, NaCl 6.41g, Na
2sO
30.002g and Proclin-3000.2ml are in 1L beaker;
2, with graduated cylinder, measure 600ml purified water in 1L beaker, fully stir, until dissolve completely; With HCl or NaOH, adjust PH, measure its scope between 7.95-8.05;
3, add after 250ml Lumi-Phos 530, with 0.2um filter, filter and collect filtrate, by purified water, be settled to 1000ml, after mixing, post label in 2-8 ℃ of refrigeration house storage, the term of validity is 12 months.
The using method of kit of the present invention is as follows:
1, add 15 μ l TNF-α calibration objects, quality-control product, sample to be measured to corresponding test tube bottom.
2, add 25 μ l enzyme labelled antibodies to each test tube.
3, add 25 μ l reinforcing agents to each test tube.
4, add 25 μ l magnetic separation agents to each test tube.
5, multitube vortex mixer vibrates gently and is placed with after the test tube rack 30s of test tube, puts 37 ℃ of water-baths 30 minutes.
6, test tube frame linking is put to magnetic separator, guarantees that every test tube all contacts with separator surface, precipitates 2 minutes, and the separation vessel that then reverses is slowly poured out supernatant.
7, concentrate is with after 10 times of purified water dilutions, adds concentrate after 100 μ l dilutions to each test tube, puts on multitube vortex mixer vibration gently and mixes 30s.
8, add 100 μ l substrate solutions and mix 3 seconds to test tube, with ready luminous detector, detect rapidly.
Clinical testing:
Case: Bronchial Asthmas 56 examples of the People's Hospital, city clinical definite, man's 29 examples, female's 27 examples, age 46-67 year, the Diagnosing Asthma standard of formulating for 2003 according to respirology branch of Chinese Medical Association asthma group (respirology branch of Chinese Medical Association asthma group. prevention and control of bronchial asthma guide. Chinese tuberculosis and breathing magazine, 2003).
Acute attack group (acute stage condition: repeatedly show effect, pant, expiratory dyspnea, uncomfortable in chest or cough medical history, bronchodilatation experiment is positive, meets the diagnostic criteria of acute phase of asthma): 38 examples.State of an illness alleviation group (paracmasis standard: through treatment or untreated symptom, sign, disappear, respiratory tract functional rehabilitation is to the front level of acute attack and maintain more than 10 days): 18 examples.Control group: all take the photograph sheet, lung function tests through medical history investigation, chest x-ray and get rid of loyalty and have the pulmonary disease may, all cases are all got rid of malignant tumour, active tuberculosis, rheumatic disease, laboratory examination, confirm without cardiovascular, breathing and liver, kidney, metabolism and endocrine system disease, nearly 2 months without the healthy population that infects history): 18 examples, man's 10 examples, female's 8 examples; Age 48-72 year.
With SPSSl0.0 statistical software, data are processed, the mean ± standard deviation for data of surveying (X ± s) represent, each organizes serum TNF-a level, between group, relatively with t, checks; P≤0.05 o'clock is that difference has statistical significance.
| Group | Control group (ng/ml) | Acute attack group (ng/ml) | Alleviation group (ng/ml) |
| TNF-alpha content | 0.178±0.011 | 0.872±0.167 | 0.235±0.049 |
Prove that thus cytokine TNF-a plays very important regulating action in the pathophysiological process of asthma.This experiment changes the gentle system of solutions of compared with normal control group to the TNF-a level in Serum of Patients with Asthma conspicuousness variation, P≤0.05.
Although above the present invention is described in detail with a general description of the specific embodiments, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements, all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (1)
1. quantitatively detect a kit of TNF-α, it is characterized in that, this kit comprises TNF-α magnetic separation agent, enzyme labelled antibody, reinforcing agent, calibration object, control product, concentrate and substrate; Described kit is prepared as follows and forms: the first step: the preparation process of TNF-α magnetic separation agent:
1) 1.0mg disuccinimidyl suberate is dissolved in 50ul DMSO, get in the 0.1mol/L PB damping fluid that 2mg TNF-alpha monoclonal antibodies is dissolved in pH9.5 to cumulative volume be 1ml;
2) with liquid-transfering gun, draw step 1) in disuccinimidyl suberate join step 1) antibody-solutions in, put room temperature 90min;
3) by step 2) solution that obtains join in concentration tube, then put in high speed freezing centrifuge under 3000g concentrated 30min to volume be 0.5ml;
4) get 0.5ml magnetic bead, add in 5ml reaction cup, put into test tube rack, through magnet adsorption, after 2 minutes, draw supernatant;
5) add step 3) antibody-solutions that obtains, mix rear room temperature reaction 4 hours;
6) add 37 ℃ of the TRIS solution 15 minutes of 0.3ml1mol/L;
7) add 1.5ml pH7.20.1mol/L PB to clean the magnetic bead of mark, mix 30 seconds, added, remove supernatant;
8) with 100ml magnetic bead, preserve liquid magnetic bead is proceeded to 125ml vial; It is 0.1%BSA that magnetic bead is preserved formula of liquid, 0.05% Tween-20,0.02%NaN
3, 20% ethanol, 4 ℃ of preservations;
9) by step 8) solution that obtains mixes according to the volume ratio of 1:1 by magnetic bead buffer solution, obtains magnetic separation agent in kit; Described magnetic bead buffer solution is that concentration is the TRIS-HCl damping fluid of 1mol/L;
Second step: enzyme labelled antibody preparation process:
1) 2.5mgTNF-alpha monoclonal antibodies is dissolved in the N of 1.0ml, in dinethylformamide, add 10mg/ml horseradish peroxidase aqueous solution and the 1.3mg carbodiimides of 1ml, after 1 hour, the carbodiimides of 1.0ml20mg/ml is added, potpourri constantly stirs, and 4 ℃ are spent the night;
2) by step 1) solution pack in bag filter, to the pH7.4PBS dialysis of 0.15M, 4 ℃ are spent the night, and collect and retain liquid; Then adding 10ml concentration is the BSA solution of 15mg/ml, and 4 ℃ store for future use; Finally by above-mentioned solution, with enzyme labelled antibody dilution, the volume ratio with 1:1000 mixes, and obtains enzyme labelled antibody; Described enzyme labelled antibody dilution is that concentration is the TRIS-HCl damping fluid of 1mol/L;
The 3rd step: reinforcing agent preparation steps:
1) take TRIS1.56g and NaCl4.23g in 1L container; With pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker of 10ml purified water, pour in above-mentioned 1L container;
2) with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely, adjust pH between 7.35-7.45;
3) take Mak330.9g in above-mentioned 1L container; Last constant volume 1000ml, after dissolving completely, filters with 0.2um filter; The 4th step:
The preparation of calibration object and the product of control:
By TNF-α compound concentration be respectively 0.10,0.20,0.40,0.80, the calibration object of 1.60ng/ml; TNF-α is mixed with to concentration is respectively 0.20, the control product of 0.80ng/ml;
The 5th step:
Concentrate preparation steps, preparation 1L:
1) take TRIS12.54g and NaCl325.6g in 1L container;
2) after taking 5g Tween-20 and adding 20ml water in 100ml container it is dissolved completely, pour in above-mentioned 1L container;
3) with pipettor, Proclin-300 is measured after 0.2ml dissolves completely in the beaker that fills 10ml purified water, pour in above-mentioned 1L container;
4) with graduated cylinder, measure 800ml purified water in above-mentioned 1L container, fully stir, until dissolve completely;
5) adjust pH, control its scope between 7.35-7.45;
6) last constant volume 1000ml, filters and get final product with 0.2um filter after dissolving completely;
The 6th step:
Substrate preparation steps, preparation 1L:
1) take TRIS2.35g, NaCl6.41g, Na
2sO
30.002g and Proclin-300 0.2ml are in 1L beaker;
2) with graduated cylinder, measure 600ml purified water in 1L beaker, fully stir, until dissolve completely, adjust pH between 7.95-8.05; 3) add after 250ml Lumi-Phos530, with 0.2um filter, filter and collect filtrate, by purified water, be settled to 1000ml, after mixing and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110399728.2A CN102495215B (en) | 2011-12-06 | 2011-12-06 | Kit for quantitatively detecting tumor necrosis factor alpha |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110399728.2A CN102495215B (en) | 2011-12-06 | 2011-12-06 | Kit for quantitatively detecting tumor necrosis factor alpha |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102495215A CN102495215A (en) | 2012-06-13 |
| CN102495215B true CN102495215B (en) | 2014-01-22 |
Family
ID=46187056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110399728.2A Expired - Fee Related CN102495215B (en) | 2011-12-06 | 2011-12-06 | Kit for quantitatively detecting tumor necrosis factor alpha |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102495215B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102998457B (en) * | 2012-07-12 | 2015-08-26 | 电子科技大学 | The Competitive assays enzyme-linked immune detection method of grass carp TNFa lpha |
| CN103823064B (en) * | 2014-03-03 | 2016-05-25 | 中华人民共和国张家港出入境检验检疫局 | A kind of vomitoxin immue quantitative detection reagent box and using method thereof |
| CN104198721B (en) * | 2014-07-28 | 2016-10-05 | 北京润诺思医疗科技有限公司 | The preparation of a kind of silica-based magnetic bead bond of GP73 (GP73) antigen and application |
| CN105467137A (en) * | 2015-11-26 | 2016-04-06 | 北京豪迈生物工程有限公司 | Free human chorionic gonadotropin beta-subunit test kit and test method |
| CN106918633B (en) * | 2017-04-24 | 2019-06-25 | 中国科学院苏州生物医学工程技术研究所 | The detection method of cytokine TNF-α based on aptamer and golden magnetic nano particle |
| CN110672857A (en) * | 2019-10-10 | 2020-01-10 | 四川大学华西第二医院 | TNF-alpha high-sensitivity Elisa detection kit and use method and application thereof |
| CN113552368A (en) * | 2021-07-21 | 2021-10-26 | 苏州立禾生物医学工程有限公司 | Tumor necrosis factor alpha detection kit and detection method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101377490A (en) * | 2007-08-30 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Magnetic microparticle separating chemiluminescence immune analysis determination reagent kit for detecting related sign object and preparing method thereof |
| CN102016552A (en) * | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | Methods and compositions for highly sensitive detection of molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2307563B1 (en) * | 2008-03-28 | 2014-08-06 | Katholieke Universiteit Leuven KU Leuven Research & Development | Mucosal gene signatures |
-
2011
- 2011-12-06 CN CN201110399728.2A patent/CN102495215B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101377490A (en) * | 2007-08-30 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Magnetic microparticle separating chemiluminescence immune analysis determination reagent kit for detecting related sign object and preparing method thereof |
| CN102016552A (en) * | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | Methods and compositions for highly sensitive detection of molecules |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102495215A (en) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102495215B (en) | Kit for quantitatively detecting tumor necrosis factor alpha | |
| CN104634980B (en) | The super quick detection kit of cardiac muscle troponin I and super quick detection method | |
| CN101738473B (en) | Treponema pallidum antibody diagnostic kit and preparation method thereof | |
| CN102072957B (en) | Hepatitis C virus antibody diagnostic kit and preparation method thereof | |
| CN101452001A (en) | Quantitative determination RBP4 kit by chemiluminescence magnetic enzymoimmune method | |
| CN103353521B (en) | Method for determining contents of biological marker and DNA through direct-reading portable glucometer | |
| CN103869085A (en) | Kit for detecting anthropogenic N terminal-b-type natriuretic peptide precursor | |
| CN103076455B (en) | Quantitative detection serum amyloid A protein kit and Synthesis and applications thereof | |
| CN107543932A (en) | The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of calcitonin | |
| CN103173420A (en) | Hybridoma cell capable of secreting anti-cardiac troponin I monoclonal antibodies and applications thereof | |
| CN102520176B (en) | Kit for quantitatively detecting interleukin 8 | |
| CN103323592B (en) | High-throughput drug rapid detection chip and system | |
| CN105842464B (en) | Joint based on up-converting phosphor technology quantitatively detects uNGAL and uCr device and preparation method thereof | |
| CN104965089A (en) | Novel platelet antibody kit using micro-column gel technique and preparing method thereof | |
| CN105259354A (en) | Kit for detecting tuberculosis T cell release gamma-interferon and use method of kit | |
| CN101320041A (en) | Colloidal gold method for fast quantitative determination of C-reaction protein and its application | |
| CN101592660A (en) | Brucellosis indirect enzyme-linked immunosorbent assay milk humoral antibody detection kit | |
| CN103048453B (en) | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof | |
| CN105424941B (en) | AKR1B10 albumen and the kit for liver cirrhosis diagnosis | |
| CN102103142B (en) | In-vitro assay method for thrombin-activatable fibrinolysis inhibitor (TAFI) content | |
| CN103048477A (en) | Nanometer magnetic particle chemiluminescence detection kit for triiodothyronine as well as preparation method and detecting method of same | |
| CN110187129A (en) | C reactive protein detection kit | |
| CN104730231B (en) | A kind of sample buffer for fluorescence immunoassay detection by quantitative and application thereof | |
| CN104569390A (en) | Quantitative detection method for gamma-interferon and kit | |
| CN109633163B (en) | procalcitonin/C reactive protein two-in-one detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: LI SHOUWEI Effective date: 20150227 Owner name: WUHAN ANNA NANO BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: REN QINGYUAN Effective date: 20150227 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 273400 LINYI, SHANDONG PROVINCE TO: 430000 WUHAN, HUBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150227 Address after: 430000 East Lake Hubei New Technology Development Zone, Wuhan high tech Avenue, No. 666 Wuhan national biological industry base project B, C, D District R & D building B1 Patentee after: An Wuhan nano Biological Technology Co., Ltd. Address before: 273400 Department of clinical laboratory, Feixian County people's Hospital, 71 health Road, Shandong, Linyi, Feixian County Patentee before: Ren Qingyuan Patentee before: Li Shouwei |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181221 Address after: 430000 East Lake New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Kersi Biotechnology Co., Ltd. Address before: 430000 Development Building B1 of Wuhan National Biological Industrial Base Project B, C and D, 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee before: An Wuhan nano Biological Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20201206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |